The use of vitamins B1, B6, B12 and B9, alone or in combination, may be effective as an adjuvant for the treatment and prophylaxis of episodic migraine in women, according to the results of a study presented at American Headache Society (AHS) 2022 Annual Scientific Meeting, held July 9-12, in Denver, Colorado, and virtually.
Recognizing that enough studies have demonstrated the effectiveness of vitamin B2 in migraine prophylaxis, researchers sought to examine the effects of supplementation with other B vitamins, including B1 (thiamin), B6 (pyridoxine), B12 (cobalamin) and B9 (folic acid). ), as well as a combination of these vitamins, in women with episodic migraine. They conducted a randomized, double-blind, placebo-controlled, 16-week clinical trial in Iran.
A total of 120 women with episodic migraine were assigned to the following 6 groups, with 20 participants enrolled in each group: (1) vitamin B1; (2) vitamin B6; (3) vitamin B12; (4) vitamin B9; (5) vitamin B complex; and (6) placebo. Paper headache diaries were used to record the number of abortifacient drugs used and the frequency of headache attacks experienced by the participants. Migraine-related disability was assessed using the Migraine-Related Disability Assessment Questionnaire (MIDAS) at baseline and after the end of the intervention.
Study results showed that mean changes in headache attack frequency were significantly decreased in all vitamin groups compared to the placebo group. Significant improvement in MIDAS scores in each vitamin group compared to the placebo group was also reported. Additionally, participants who received 12 weeks of supplementation with vitamin B9, vitamin B1, vitamin B6, vitamin B12, and vitamin B complex had a significant decrease in the number of abortifacient drugs used. compared to those treated with a placebo.
The researchers concluded that “further large trials with long-term follow-up will be needed to confirm our findings.”
Nematgorgani S, Jahromi R, Jafari E, et al. Effects of B vitamin supplementation on migraine characteristics and disability in women with episodic migraine: a randomized, double-blind controlled trial. Presented at: AHS 2022 Annual Scientific Meeting; July 9-12, 2022; Denver, Colorado. Poster 161.